Pediatric Heart Transplant - Alloantibodies Impact Study

Alloantibodies in Pediatric Heart Transplantation

Protocol Description

This multi-center study examines whether antibodies affect the outcomes of pediatric heart transplants. Antibodies are proteins in the blood that the body makes to fight off infections. Although white blood cells are known to play a significant role in organ rejection, researchers theorize that a child’s body might also use antibodies against a newly transplanted heart. This study will measure antibodies in the blood, and researchers will perform tests to see how they might affect the heart. Another goal is to develop a blood test to help predict when antibodies are damaging the heart. Children’s Hospital of Pittsburgh of UPMC is one of the seven hospitals in the Clinical Trials in Organ Transplantation in Children (CTOT-C) consortium pursing this research.

Study Level: CTOT-C 04

Eligibility Criteria

Subject to certain exclusions, this study is only open to prospective pediatric heart transplant patients.
Males: Up to age 21
Females: Up to age 21


Blood draws will be taken at various intervals, starting from prior to transplant through three years after the transplant. Researchers will be testing blood samples for antibodies that may react with the donor heart.
Visits: None beyond normal care for heart transplant
Duration: 3 years

Status: Enrolls from Eligible Heart Transplant Patients

Source(s) of Support

National Institute of Allergy and Infectious Diseases
National Heart, Lung and Blood Institute

Primary Investigator

Brian Feingold, MD

Contact Information

For information, please contact:
Jane Luce, MHP, CHES